Y-Prime Technologies LLC, an eClinical products and consulting company, is expanding its suite of eClinical software solutions with Prime Publisher™, a concatenation tool designed to streamline the content review process and combines multiple data forms into a single, navigable format.
"Prime Publisher offers an integrated, component-based approach to building document content and the flexibility to combine exactly what the reviewer needs to see and comment on," explains Dan Glass, vice president of Enterprise Content Management at Y-Prime LLC. "Focusing reviewers and their feedback in large documents containing multiple pieces of information is crucial to reducing re-work and cycle times. Prime Publisher provides much of the functionality of a full-blown system, while being easier-to-use at a fraction of the cost."
Prime Publisher simplifies difficult processes such as reviewing large sections of the eCTD. For example, a Module 2 Quality Overview contains cross-references to information contained in Module 3 Drug Product and Drug Substance Manufacturing and Stability information. A typical Module 3 might contain 200 or more documents for an initial application. Prime Publisher enables an author to select the overview and the relevant Module 3 documents combining them into a single review document. It reduces time spent flipping between submission components during review and approval processes, especially where business processes and supporting technology allows the reviewer/approver to assign workflow outcomes to all documents simultaneously.
Prime Publisher also helps in preparation for Clinical Study Reports (CSR) to a global audience. The tool allows the author to prepare a modular or component-based report to accommodate regional regulatory differences of information provided.
Prime Publisher requires minimal training and integrates with industry-leading EDMS systems or fileshares. It offers the flexibility to select virtual documents and leverage an EDMS clipboard (such as inside Documentum and other Documentum based applications) and also allows multi-select to easily integrate into existing business practices.
Earlier this year, Y-Prime launched Prime IVRS and Prime eMVR products which provide high-level capabilities for bio-pharmaceuticals and CROs as well as larger sponsors who want to enhance or replace their current systems. Both Prime IVRS and Prime eMVR are designed to work out-of-the-box and seamlessly share data with existing CTMS systems as well as other eClinical applications.
All Y-Prime products are backed by 24/7 U.S. based support, project management and development capabilities.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.